Last updated on August 2017

Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant


Brief description of study

Proof of concept, open-label single center study for the donation of HCV positive kidneys to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.

Detailed Study Description

The study objective is to determine if the administration of grazoprevir and elbasvir (with or without ribavirin) for 12-16 weeks after kidney transplantation prevents the spread of HCV infection from a donor kidney with known HCV genotype 1 or 4 infection to a HCV negative recipient as evidenced by a negative HCV viral RNA at 12 weeks post treatment

Clinical Study Identifier: NCT02945150

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Raymond T Chung, MD

Massachusetts General Hospital
Boston, MA United States
  Connect »